Pharmacokinetic and pharmacodynamic target attainment of ceftazidime in adult patients on general wards with different degrees of renal function: a prospective observational cohort study.

No registrations found.

Ethical review	Not applicable
Status	Pending
Health condition type	-
Study type	Observational non invasive

Summary

ID

NL-OMON25634

Source
NTR

Brief title
PK-PD cefta

Health condition

Bacterial infections

Sponsors and support

Primary sponsor: Amsterdam UMC - location Academic Medical Centre (AMC), University of Amsterdam
Source(s) of monetary or material Support: Amsterdam UMC - location Academic Medical Centre (AMC), University of Amsterdam

Intervention

Outcome measures

Primary outcome

PK-PD target attainment of 50%T>MIC during the first 24 hours of therapy

Secondary outcome

50%T>MIC after 24-48 hours of therapy
PK-PD target attainment of 100%T>MIC during the first 24 hours of therapy
To compare ceftazidime exposure at 24 hours and 24-48 hours after start of treatment between three different renal function groups in terms of AUC and Cmin
Clinical outcome

Study description

Background summary

Prospectively investigate whether ceftazidime, in the currently recommended dosing regimen, results in the PK/PD target attainment defined as 50%T>MIC in the first 24 hours of treatment for adult patients on general wards with adequate and impaired renal function receiving regular and recommended reduced doses of ceftazidime.

Study objective

Exploratory study prospectively investigating (validating) the currently recommended dosing regimen of ceftazidime.

Study design

Thee venapunctures in a time period of 48 hours

Intervention

Three venapunctures

Contacts

Public

Amsterdam UMC, location Academic Medical Centre (AMC), University of Amsterdam
Suzanne L. de Vroom

0031 (0)6 29189028
Scientific
Amsterdam UMC, location Academic Medical Centre (AMC), University of Amsterdam
Suzanne L. de Vroom

0031 (0)6 29189028

Eligibility criteria

Inclusion criteria

Receiving ceftazidime therapy intravenous (iv) as part of standard care
Age ≥ 18 years
Admitted to a general ward of Amsterdam UMC - location AMC
Informed consent is obtained

Exclusion criteria

Renal replacement therapy during treatment with ceftazidime
Patients admitted to the intensive care unit (ICU)
Severely burned patients, defined as a burned surface ≥ 10%
Patients with cystic fibrosis
Informed consent is not obtained

Study design

Design

Study type:	Observational non invasive
Intervention model:	Other
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

Recruitment

NL

Recruitment status:	Pending
Start date (anticipated):	03-07-2019
Enrollment:	40
Type:	Anticipated

IPD sharing statement

Plan to share IPD: No

Ethics review

Not applicable
Application type: Not applicable

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL7864
Other	METC AMC : METC 2019_159

Study results